Full-Time

Director – US Market Access Marketing

Rare Cardio

Posted on 10/4/2025

Deadline 10/8/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$169.7k - $282.9k/yr

+ Bonus

Cambridge, MA, USA + 8 more

More locations: Tampa, FL, USA | Bothell, WA, USA | San Bruno, CA, USA | Phoenixville, PA, USA | La Jolla, San Diego, CA, USA | Highland Park, IL, USA | Groton, CT, USA | New York, NY, USA

Hybrid

This position is hybrid and requires working onsite 2 to 3 days per week. Not eligible for Relocation Package.

Category
Growth & Marketing (1)
Required Skills
Marketing
Requirements
  • Bachelor’s degree required; MBA, PharmD, PhD or relevant graduate degree preferred
  • 8+ years of combined experience within the U.S. pharmaceutical/healthcare market with primary focus within strategy for Marketing and/or US Market Access, Customer/Account Management, Access/Customer Marketing, and/or Healthcare consulting
  • Demonstrated ability to quickly identify insights and develop effective strategies & tactics based on these insights
  • Strong business acumen and analytical skills to help set priorities & strategies, and track record in leveraging insights to help guide the decision-making process
  • Ability and desire to work effectively & collaboratively in a team-based environment with many internal stakeholders
  • Proven record of operating in a fast-paced, high-energy environment
  • Desire to work in an ambiguous environment, set priorities, and define workstreams as needed
Responsibilities
  • Ensure successful revenue maximization of Vyndamax by leading the Brand Access strategy and developing annual Brand Access Plan
  • Mature the development of the Customer/Brand engagement strategy for top accounts within Medicare, Commercial and other channels as appropriate based on clinical and economic value
  • Evolve the Vyndamax value narrative and associated materials as needed to engage payer customers in their decision making based on clinical and economic value
  • Collaborate with key stakeholders to set and monitor access goals and plan strategies accordingly to maximize GTN
  • Drive and inform key decisions regarding Vyndamax access assessments for and negotiations in a complex and continuously evolving market
  • Lead and manage Brand Access Matrix Team for Vyndamax, a cross-functional matrix team of various access subject-matter experts, to align, develop and advance all access-related strategies and activities across key functions that support access
  • Develop and implement quarterly POA priorities and call to action with Account Management team
  • Proactively identify and address key barriers to payer access and performance by applying advanced understanding of and experience with contracting and pricing strategies, payer analytics, and payer market trends across brand lifecycle, and market channels
  • Manage USMA Brand budget and secure appropriate funding for Brand specific strategies and tactics from commercial partners
Desired Qualifications
  • Understanding of US market access marketing initiatives focused on access customers, for both medical and pharmacy benefit products
  • Knowledge of key marketplace dynamics and healthcare trends (Inflation Reduction Act’s impact on Medicare, 340B dynamics, channel management considerations, pharmacy benefit therapies etc.) for Vyndamax
  • Significant visibility within the global and US Value and Access teams and with USMA partners: Brand marketing, Contracting, US Market Access leadership team, RC, Global Access teams etc.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE